- Investing Ideas
- /
- South Korean Pharmaceuticals & Biotech Undervalued based on future growth
South Korean Pharmaceuticals & Biotech Undervalued based on future growth
Results
5
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
5 companies
Hugel
Market Cap: ₩2.5t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩235,000.00
7D
3.5%
1Y
-12.0%
L&C BIOLTD
Market Cap: ₩1.5t
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine.
A290650
₩62,400.00
7D
-0.3%
1Y
130.3%
Medy-Tox
Market Cap: ₩859.2b
Operates as a biopharmaceutical company in South Korea.
A086900
₩122,400.00
7D
4.1%
1Y
-1.9%
DongKook Pharmaceutical
Market Cap: ₩764.1b
Produces and sells pharmaceutical products in South Korea and internationally.
A086450
₩17,080.00
7D
-2.0%
1Y
4.8%
Dong-A Socio Holdings
Market Cap: ₩693.1b
Engages in the pharmaceutical business in South Korea.
A000640
₩107,700.00
7D
-2.3%
1Y
6.0%